Background: Improvement of lymphoma therapy is largely driven by clinical therapy optimization protocols (TOPs).
introduction Therapy optimization protocols (TOPs) have been successful instruments to improve oncologic therapy regimens for many years. In the 1980s, the proportion of disease-free 5-year survival increased from 50% to 80% among patients with Hodgkin lymphoma (HL) [1] . Today, even advanced stages of HL can be cured. Foltz et al. [2] investigated overall survival (OS) and progression-free survival (PFS) in adolescent (16-21 years) and adult (22-45 years) HL patients. Rates ranged between 91% in adolescents and 89% in adults for 10-year OS. Rates for 10-year PFS were 77% in adolescents and 80% in adults. Particularly among older patients (>45 years) with HL, Brenner et al. [3] recently observed a major improvement in long-term survival. The authors assessed trends in age-specific 5-and 10-year relative survival of patients with HL registered in the Surveillance, Epidemiology, and End Results Program of the United States. The increase in 10-year relative survival was 25% in HL patients aged 45-59 years and 23% in HL patients >60 years.
For non-Hodgkin lymphoma (NHL), survival rates also increased significantly but differed depending on the localization and stage of the disease at the time of diagnosis. In the early 1980s, a disease-free 10-year survival was observed for only 35% of the NHL patients with localized histiocytic NHL stage II [4] . Recently, the French GEOLAMS study (Groupe Ouest Est Leucémies Aiguës Myéloblastique Study) by Bernard et al. [5] found a rate of 82% for the 10-year disease-free survival (after complete remission) for localized high-grade non-Hodgkin lymphoma (hgNHL) treated with high-dose combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone. Pulte et al. [6] found the most pronounced improvement in relative survival for patients <45 years of age. The 5-year survival increased by 26.8 percentage points from 1990 to 1992 and 2002 to2004 and the 10-year survival increased by 27.1 percentage points.
However, these encouraging therapy improvements have been observed in the context of standardized TOPs, which include a high degree of standardization, quality control, and strict inclusion and exclusion criteria. Clinical study centers usually select only a subgroup out of the total of their patients and these patients again represent only a subgroup of all patients prevalent in the general population. Our study 'Therapy optimization protocols in cytostatic and radiotherapy of patients with HL and hgNHL (TOPiCS-ML)' aimed to investigate in a population-based approach whether the patients treated in TOP for HL and hgNHL represent the entire group of patients in the general population. If there should be systematic differences, and, hence, evidence for selection, the study should analyze the relevant parameters and their respective impacts.
patients and methods
The case-base for TOPiCS-ML was ascertained in a population-based incidence study conducted from 1998 to 2001 in Northern Germany [7] . The study area comprised six counties surrounding the City of Hamburg (Harburg, Herzogtum Lauenburg, Lüneburg, Pinneberg, Steinburg, and Stormarn) with a population of 1.1 million. Data ascertainment was carried out by specifically trained study personnel in 20 regional hospitals, 2 university hospitals, all outpatient cancer treatment facilities, and all pathology and cytology laboratories in the study area, in neighboring counties, and in the City of Hamburg. After record linkage, the incidence study identified 6358 individual patients with hematological monoclonal diseases with malignant clinical course and with a first diagnosis in the time period from 1984 to 1998. Data on patients with residency in the six counties and diagnosed primarily with HL from 1988 to 1998 or with hgNHL within the period of 1994-1998 were extracted from the database of the incidence study (n = 743). The time periods for primary diagnosis of these populationbased patients correspond to the recruiting periods of the respective TOPs, which recruited and randomized clinical patients nationwide. All institutions involved in the diagnostics and/or treatment of these 743 patients were contacted and agreed to participate in the new study. Patients' data from the incidence study were used as basic information. In TOPiCS-ML, all hospitals, clinics, and outpatient facilities involved in the diagnosis and/or treatment of the index patients were revisited from 2001 to 2005. For each of the 743 patients, trained personnel abstracted all clinical parameters and other information necessary to evaluate the status with respect to the inclusion and exclusion criteria of the respective TOP. All available data sources (e.g. patients' files and pathology and histology reports) were included and patient information documented in detail in an anonymized computer-assisted format.
The standardized formats for data abstraction were developed a priori on the basis of the criteria applied by the respective multicenter clinical trials conducted in Germany over the years of the study period for both disease entities considered in TOPiCS-ML.
From 1988 to 1998, the German Hodgkin Study Group (GHSG) conducted six multicenter randomized controlled trials (Hodgkin's disease (HD) studies: HD 4-HD 9) to evaluate new clinical therapy regimens for early, intermediate, and advanced stages of the disease [8] [9] [10] [11] [12] [13] [14] . These six TOPs served as the basis for our analysis of whether the population-based patients from the incidence study with HL would have met the inclusion criteria of the respective TOP pertinent for their tumor stage and year of first diagnosis. For patients with hgNHL, we applied the criteria of the German trial NHL-B1/B2 [15, 16] , a multicenter study conducted during 1994-1998 by the German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL; [17] ).
The inclusion criteria were checked for each patient identified in the population-based incidence study in the order documented in the study protocols for both entities, beginning with age limits, followed by physical condition, medical history, and laboratory values. Variables associated with reduced compliance (known depression, alcohol or drug addiction) lead to exclusion. If the reasons for noncompliance documented in patients' files were less clear (e.g. the item 'willingness to follow treatment regimen'), they were individually discussed with the physicians responsible for inclusion in the respective TOP study center. Trial physicians were asked to decide on inclusion or exclusion of the patient according to their practice in the respective trial. For exclusion, a patient needed to miss at least one of the inclusion criteria or to meet at least one exclusion criterion of the respective TOP. If several exclusion criteria applied, the exclusion reason for this analysis was assigned to the criterion ranking highest in the list of the respective trial (Tables 2 and 3 ).
In a pilot study from October 2001 to January 2002, data ascertainment was implemented and tested in two major hospitals in Hamburg with respect to availability, accessibility, completeness, and validity of data on variables of interest in patients' files and other primary (i.e. patient related) or secondary (i.e. aggregated) data sources. This pilot study allowed also for adjustments of the standardized documentation form, the data flow design, and the technical procedures, which were checked for compatibility with pertinent data protection legislation.
During data ascertainment of the TOPiCS-ML study, we abstracted detailed information on clinical diagnoses, physical condition, medical history, and an array of disease-specific risk factors. Additionally, the most recent vital status was obtained from the treating facilities and from regional population registries for all target patients in our population-based approach.
Patients who had participated in one of the respective clinical protocols were identified on the basis of rosters maintained by the two national clinical study groups (GHSG and DSHNHL). Specifically, patients with HL were checked for participation in the respective TOPs HD 4-HD 9. hgNHL patients were checked for participation in the German NHL-B1/B2 study protocol.
Finally, TOP participants and nonparticipants were compared for baseline criteria and the prevalence of risk factors and prognostic factors to assess the direction and, if any, the degree of selection. Differences in patient characteristics were tested for significance by the chi-square test and, if required, by the Fisher's exact test.
The design and procedures of the study TOPiCS-ML have been approved by the Federal State of Hamburg Data Protection Board and by the Ethics Committee of the Board of Physicians of the Federal State of Bremen, Germany, in charge of the incidence study which had been conducted at the Bremen Institute of Prevention Research and Social Medicine [7, 18] .
results
We identified and extracted 356 incident cases with a diagnosis of HL and 387 with hgNHL from the database of the incidence study. Of these, 59 patients had to be excluded because their files could not be retrieved in any of the clinical institutions (28 HL, 31 hgNHL). We were able to complete data ascertainment of baseline characteristics and risk factors for 92.1% of all 743 selected patients.
In some cases, the active data assessment in TOPiCS-ML revealed a different primary diagnosis or a different date of the initial diagnosis compared with the information collected in the original article Annals of Oncology preceding incidence study. Due to this updated information, another 47 patients (6.3%) were excluded from further analysis. In total, 637 (85.7%) of the population-based patients were eligible for analysis (Table 1) .
Both the protocols for HL (HD 4-HD 9) and the TOP NHL-B1/B2 were strictly age limited [>16 years (HL) and >18 years (hgNHL) and <75 years], which caused the exclusion of 15.2% of the population-based identified HL patients (Table 2 ) and of 27.4% of the population-based hgNHL patients (Table 3) .
To assess eligibility as a participant for the respective TOPs, every newly diagnosed patient's detailed medical history was taken and each patient was physically examined. Applying these two dimensions to further analysis of the 309 population-based HL patients, we found another 5.5% who would have failed inclusion because of severe additional comorbidities like, for example, chronic obstructive pulmonary disease, heart failure (New York Heart Association Functional Classification, NYHA ‡ 2), severe infection, or severe uncontrollable hypertension ( Table 2 ). Another 5.8% of the HL patients would not have been accepted as TOP patients because of documented reduced compliance. Objective parameters like laboratory results were decisive for exclusion for only few patients (Table 2 ). In total, 198 of 309 patients (i.e. 64%) who were identified in the population-based incidence study remained as eligible for the respective TOPs HD 4-HD 9.
The protocol of the TOP NHL-B1/B2 excluded specific subgroups within the diagnostic entity of hgNHLs. In total, 24 (7.3%) of the population-based patients with the specific diagnosis of, for example, cutaneous or cerebral NHL without generalization would not have been eligible for NHL-B1/B2 (Table 3 , lines 7-10). Forty-five (13.7%) patients >18 years and <60 years of age were observed with lactate dehydrogenase above the upper normal value at the time of diagnosis and had to be excluded according to protocol. Twenty-one (6.4%) patients showed impairments of cardiac, pulmonary, hepatic, or renal function and, similar to the HL group, a significant proportion of the population-based NHL patients (3.7%) would have been excluded because of reduced compliance (Table 3) . Finally, 97 (29.6%) patients would have been eligible for the hgNHL TOP NHL-B1/B2.
Datasets with selected variables (diagnosis, date of diagnosis, sex, age at diagnosis, date of birth) of all patients who were potentially eligible for inclusion in the respective TOPs were transferred to the study centers for anonymous record linkage with the TOP databases. This record linkage revealed that only 71 of 198 eligible HL patients (35.6%) and 11 of 97 eligible hgNHL patients (11.3%) had actually been randomized in the respective TOPs. Five patients (HL two; hgNHL three) had been enrolled in other clinical trials of the GHSG and the DSHNHL. Hence, comparisons of population-based nonstudy versus TOP patients were on the basis of 125 (40.5%) of the initially selected incident HL cases and 83 (25.3%) of the hgNHL cases in the category of nonstudy patients ( Table 4 ).
The proportion of male patients is higher in the populationbased nonstudy group than in the TOP group for both HL and hgNHL patients (Tables 5 and 6) .
Compared with TOP patients, age at diagnosis was higher in the population-based group that fulfilled all inclusion criteria but did not participate in the respective TOP (median age at diagnosis: HL study versus nonstudy: 32 versus 36 years or hgNHL study versus nonstudy: 60 versus 62 years). The proportion of HL patients with the risk factor age at diagnosis ‡45 years was higher among population-based nonstudy patients (HL study versus nonstudy: 24.8% versus 34.4%, P = 0.0209; Table 5 ). The proportion of patients in higher tumor stages was higher among TOP patients (hgNHL study versus nonstudy, tumor stage III or IV: 40.5% versus 28.9%, P = 0.036; Table 6 ). In both entities, the proportion of patients with disease-specific risk factors (e.g. extranodal involvement) was higher among the study patients (Tables 5 and 6 ).
discussion and conclusions
The definition of inclusion criteria in multicenter TOPs is necessary to reduce heterogeneity and to optimize comparability. However, as a consequence, a certain proportion of all patients in the general population are excluded from participation in these study protocols. This finding is consistent with the result of a descriptive study in Great Britain. Corrie et al. [19] investigated the limiting factors in recruitment of patients to clinical trials in cancer research. If a clinical trial was available, the eligibility criteria excluded over half of the patients in their study. A similar study on selection of patients for randomized trials in Australia found only 75 of 497 (15%) NHL patients to be eligible according to the specified criteria of the trial [20] .
In our study, 15% of the incident cases with HL and 27% of the NHL patients in the general population occur outside the age ranges defined for the respective clinical TOPs, mostly at Table  3 ). A systematic review of randomized controlled trials (RCTs) published in high-impact general medical journals [21] found that patients were excluded due to age in 72.1% of all trials (all age groups) investigated. Patients >65 years were excluded in 38.5% of the RCTs [21] .
Taking into account that HL shows a second peak in the age group >55 [22] [23] [24] , that the largest increase in incidence of hgNHL was observed for the age groups >60 [25, 26] , and that the demographic change increases the population in older age groups both in proportion and in absolute numbers [27] , our findings emphasize once more that TOPs which address lymphoma therapy particularly for patients of old age are urgently needed. Clinicians have started to search specifically for therapy regimens for elderly lymphoma patients, who need more effective yet tolerable treatment regimens [28] [29] [30] [31] .
Comorbidity is a major problem in the clinical management of lymphoma patients. The exclusion criterion of comorbidity is ranked at the fourth position for HL patients in our study. The review of Van Spall et al. [21] showed that in 81.3% of the published RCTs, patients were excluded due to medical comorbidities. Using the population-based Eindhoven Cancer Registry in The Netherlands to assess the independent prognostic effect of comorbidity in lymphoma patients, van Spronsen et al. [32] found that in 1551 unselected lymphoma patients, the prevalence of serious comorbidity was 58% for patients with HL who were >60 years of age and 66% for patients with NHL who were >60 years of age. The administration of chemotherapy declined in the presence of comorbidity for elderly patients with early-stage HL and elderly patients with aggressive NHL. Comorbidity led to a decline in 5-year survival by 10%-20%. To investigate how important the individual comorbidity is for cancer treatment and therapy outcome, the integration of comorbidity, rather than its exclusion, in therapy optimization studies is required [32, 33] . Leukopenia (white blood cell count < 3000/ll) 1 0.3 7
Creatinine clearance < 60 ml/min, serum bilirubin > 2 mg/dl, GOT > 100 U/l, or GPT > 100 U/l Despite exclusion due to restricted age limits, specific physical conditions, required laboratory parameters, or comorbidity, there were many patients, who would have met all protocol criteria but were, nevertheless, treated outside the TOPs. This was the case for two-thirds of the patients with HL (n = 125 of 198), who were eligible for the respective optimization protocols but did not participate. In the population-based group of hgNHL patients, we identified 83 of 97 eligible patients as nonparticipants, who would have met all necessary physical prerequisites for inclusion into the TOP NHL-B1/B2. Population-based research into the determinants of participation in randomized therapy optimization studies in cancer is still limited. In a survey conducted among oncologists (n = 137) and their patients (n = 170) in Pennsylvania, patients identified fear of side-effects as the greatest barrier to clinical trial participation, whereas oncologists ranked this psychological barrier as least important to their patients [34] . Both, oncologists and patients, ranked highly the fear of receiving a placebo. These results indicate the potential of further improvement of patient communication to optimize trial participation.
Finally, few studies have investigated whether therapy regimens outside respective TOPs for NHL patients achieve similar outcomes [35, 36] . Using a more general approach on cancer patients in clinical trials, Peppercorn et al. [37] stated on the basis of 26 comparisons that there were only insufficient data to conclude that trial patients have better outcomes. In a next step, the group of population-based nonstudy patients we have identified in this study will be analyzed in comparison with the TOP participants to evaluate if both groups of patients gain equally from the treatment received. In nonstudy group, available for n = 115 patients and in study group, for n = 4900. b In nonstudy group, available for n = 117 patients and in study group, for n = 4927. c In nonstudy group, available for n = 124 patients and in study group, for n = 4942. d In nonstudy group, available for n = 124 patients and in study group, for n = 4933. e In nonstudy group, available for n = 105 patients and in study group, for n = 4938. Patients of the population-based group who were eligible for one of the TOPs but were treated outside the respective TOP.
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